Table I. OMV-based antigen selection. Antigens were selected from the total proteins quantified in OMV based on the following criteria: Bvg regulation, localization prediction, and abundance. Percentages refer to the total protein composition of OMV from either Bvg+ or Bvg− phase in the three biological replicates.
| Accession | Protein name [Bordetella pertussis Tohama I] | Replicate 1 |
Replicate 2 |
Replicate 3 |
|||
|---|---|---|---|---|---|---|---|
| % Bvg+ | % Bvg− | % Bvg+ | % Bvg− | % Bvg+ | % Bvg− | ||
| NP_882013.1 | BrkA autotransporterab | 12.96% | 0.08% | 10.69% | 0.00% | 19.21% | 0.01% |
| NP_880571.1 | FHA filamentous hemagglutinin/adhesinca | 17.95% | 0.02% | 15.33% | 0.00% | 1.43% | 0.00% |
| NP_879839.1 | 69K pertactin autotransporterca | 5.44% | 0.01% | 11.48% | 0.00% | 10.68% | 0.00% |
| NP_879974.1 | TcfA tracheal colonization factorab | 4.26% | 0.00% | 3.28% | 0.00% | 6.95% | 0.00% |
| NP_879893.1 | BipA outer membrane ligand binding proteinab | 1.56% | 0.33% | 5.27% | 1.16% | 9.06% | 0.17% |
| NP_879104.1 | SphB1 autotransporter subtilisin-like proteaseab | 6.28% | 0.00% | 6.71% | 0.00% | 0.48% | 0.00% |
| NP_880953.1 | Vag8 autotransporterab | 5.04% | 0.01% | 4.39% | 0.00% | 3.53% | 0.00% |
| NP_879666.1 | BfrD TonB-dependent receptorb | 1.55% | 0.02% | 1.42% | 0.00% | 2.48% | 0.00% |
a = known B. pertussis protective antigens.
b = antigen selected for further analysis.
c = antigen currently included in a commercial vaccine.